DuPont (DD)
NYSEMaterialsSpecialty ChemicalsSnapshot 2026-07-09
$134.82-1.57%
Close 2026-07-09 · 1-day change
Reading DD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DD free→NYSEMaterialsSpecialty ChemicalsSnapshot 2026-07-09
Reading DD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DD free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Specialty Chemicals is in recovery. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
DuPont's growth depends on achieving 4% organic growth in 2026. The company recently beat earnings expectations with a 14.6% surprise. It trades at 43× P/E, which is 1.9× the peer median of 22.3. The market is pricing in more growth than we forecast, indicating expectations look full. A specific risk is the potential for a credibility hit if guidance is cut. Peer multiples imply a price about 195% below where it trades; this read is provisional.
Trailing returns as of 2026-07-09. DD is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 17 analysts currently covering DD (as of Jul 2026).
Based on 3 Wall Street analysts offering 12-month price targets for DD in the last 4 months.
A consensus fair price across 14 valuation methods, at three horizons. Current price $134.82. As of 2026-07-09. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Specialty Chemicals — fair value, gap to price, and forward P/E.
Legal issues could impact growth and capital allocation.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-09. EPS is implied from price ÷ P/E. Not investment advice.
Current $134.82
The last 12 months of price, then the range of analyst 12-month targets from today’s $134.82.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Legal issues could impact growth and capital allocation.
Threatens: Raise full year 2026 EPS guidance
Concerns about Q3 guidance may impact EPS expectations.
Advances: Achieve 4% organic growth in 2026
New product launch supports growth in targeted markets.
Advances: Align 2026 guidance with medium-term targets
Achieving renewable electricity aligns with sustainability goals.
Advances: Achieve 4% organic growth in 2026
New product launch supports organic growth objectives.
Advances: Align 2026 guidance with medium-term targets
Certification enhances product credibility and aligns with growth targets.